# Efficacy and Safety of FDA-approved Anti-amyloid-β Immunotherapies in Early Alzheimer’s Disease: A Systematic Review and Meta-analysis of Phase III Clinical Trials

This is all the code used in research: Efficacy and Safety of FDA-approved Anti-amyloid-β Immunotherapies in Early Alzheimer’s Disease: A Systematic Review and Meta-analysis of Phase III Clinical Trials.
The code was provided for more reproducibility of the research

- meta-analysis and meta-regression was performed using R language (R 4.2.2) with meta and metafore packages
- A fixed/Random effect model was conducted to calculate pool MD or RR with a corresponding 95% confidence interval, and Heterogeneity.
- Publication bias was determined by funnel plot

### How to use
- 
